TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01593033

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil and Micronutrient Supplementation
Description: 0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months~1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Supplement
Description: 1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
Study: NCT04422119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-Foam dressing
Description: Application of a multi-layer foam dressing with Safetac in surgical wound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Care of surgical wound with povidone-iodine and a gauze dressing with plaster.
Study: NCT04064814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flunarizine 5mg
Description: Flunarizine 5mg once daily,orally for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flunarizine 5mg
Description: Flunarizine 5mg once daily,orally for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid 300mg
Description: Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks
Study: NCT04390321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLMcare
Description: Participants will undergo 20 sessions of computerized cognitive and physical training, during a 2 month period. Both components have a duration of 30 minutes and are consecutive, but their sequence is pseudo-randomized. All sessions are conducted under supervision. Cognitive training uses the greek adaptation of the BrainHQ software (Posit Science Corporation), utilizing audiovisual stimuli, and targets memory, attention, cognitive-processing speed, orientation and social skills. Physical training is based on the WebFitForAll protocol and uses the motion sensor device Kinect. It consists of warm-up, aerobic, flexibility, strength, balance and cool down exercises.
Study: NCT02439749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symplicity Spyral™ multi-electrode renal denervation system
Description: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
Study: NCT03715998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: 1 or 2 capsules administered orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firibastat
Description: 1 or 2 capsules administered orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firibastat
Description: 1 or 2 capsules administered orally, twice daily
Study: NCT01019473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03396666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemouv
Description: Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
Study: NCT01227278

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Description: Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
Study: NCT01131572

Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylcysteine NAC
Description: N-acetylcysteine in the treatment of Bulimia Nervosa
Study: NCT03095313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-NaF
Description: At baseline a target dose of 125 MBq 18F-NaF will be administered intravenously to all subjects who will then undergo dual cardiac and respiratory-gated PET-CT imaging of the heart and aortic valve. 125ml of iodine-based contrast agent (iohexol \[Omnipaque™\]) will be given for the CT. Nitroglycerin will be given to increase the size of the coronary arteries and a possible dose of metoprolol may be given to control target heart rate.~Repeat contrast-enhanced CT of the heart and aortic valve will be conducted at Year 2 to investigate to investigate whether 18F-NaF activity predicts progression of calcification in prosthetic valves.
Study: NCT00074737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cenersen
Description: cenersen with standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cenersen
Description: cenersen with standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cenersen
Description: cenersen with standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: standard of care for AML

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: standard of care for AML

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: standard of care for AML

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: standard of care Ara-C and High dose Ara-C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: standard of care Ara-C and High dose Ara-C
Study: NCT00793494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probaclac
Description: Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo composition matodextrin, gelatin, ascorbic acid, soya
Study: NCT00786279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ethanol
Description: 15 gm ethanol daily for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol-free beverage
Description: 0 grams ethanol daily for 6 months.
Study: NCT03801382

Intervention type: DEVICE
Group type: OTHER
Intervention: IntelliSpace Cognition (ISC)
Description: Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.

Intervention type: DEVICE
Group type: OTHER
Intervention: IntelliSpace Cognition (ISC)
Description: Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
Study: NCT04449926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus of Calmette and Guerin (BCG)
Description: Prime and boost vaccination
Study: NCT04216238

Intervention type: BEHAVIORAL
Intervention: quasi-experimental Pre-test/Post-test design
Description: surveys to document progress
Study: NCT04600557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Describing a shameful experience using a self-compassionate prompt
Description: Participants will be instructed to describe a shameful experience to two confederates using a self-compassionate prompt

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Describing a shameful experience using a self-compassionate prompt
Description: Participants will be instructed to describe a shameful experience to two confederates using a self-compassionate prompt

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receiving compassionate responses from confederates
Description: Following the participant's description of a shameful experience, two confederates will respond with compassionate responses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receiving compassionate responses from confederates
Description: Following the participant's description of a shameful experience, two confederates will respond with compassionate responses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Describing a shameful experience using a neutral prompt
Description: Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Describing a shameful experience using a neutral prompt
Description: Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receiving no response from confederates
Description: Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Receiving no response from confederates
Description: Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response
Study: NCT02619175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke Subjects Perturbation-Based Balance Training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Subjects Weight Shifting and Gait training
Study: NCT03940222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive Binocular Treatment
Description: The specified system which stimulate the fovea of the amblyopic eye directly by detailed and movable objects, while the fixation of the non- amblyopic eye will be focused on fixed targets.
Study: NCT04470297

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramelteon 8mg
Description: Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon 8mg
Description: Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days
Study: NCT04231071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onlay Mesh group
Description: Primary suture repair with a small only mesh on the closed defect

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Onlay Mesh group
Description: Primary suture repair with a small only mesh on the closed defect
Study: NCT03368196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: An antibody drug conjugate
Study: NCT02049411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: physiological solution
Description: physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: physiological solution
Description: physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
Study: NCT03179761

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Inactivated Influenza Vaccine
Description: Standard Dose Quadrivalent Influenza Vaccine given intramuscularly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: High Dose Trivalent Influenza Vaccine given intramuscularly
Study: NCT01595087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteodex
Description: Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
Study: NCT03940222

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Patching Therapy
Description: Patching of the dominant eye with better best corrected visual acuity
Study: NCT03013738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growing Pro-Social Program
Description: GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment As Usual
Description: TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
Study: NCT01767896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: subcutaneous (sc)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: approved egg-derived TIV
Description: subcutaneous (sc)
Study: NCT00766519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: volume optimization
Description: Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~  + systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is \> 10%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard volume administration
Description: Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV
Study: NCT02838043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probio'Stick
Description: A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
Study: NCT04036890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% minocycline hydrochloride controlled-delivery system (MHS)
Description: The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: It is the same gel as MHS but without active ingredient minocycline hydrochloride.
Study: NCT01475357

Intervention type: OTHER
Group type: OTHER
Intervention: Arm 1: NPO by mouth pre-operative
Description: Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Fresh Breast Milk pre-operative
Description: Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
Study: NCT00547482

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TANTALUS(TM) System
Description: All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TANTALUS(TM) System
Description: All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation).
Study: NCT02819414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol drops
Description: 15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.25 ml/kg/dose x 4/day of sterile water to be given for three days
Study: NCT03017183

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EBUS-TBNA
Description: Endobronchial ultrasound guided transbronchial needle aspiration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EBUS-TBNA
Description: Endobronchial ultrasound guided transbronchial needle aspiration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endobronchial forceps biopsy
Description: Conventional endobronchial forceps biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endobronchial forceps biopsy
Description: Conventional endobronchial forceps biopsy
Study: NCT01460446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aviva Expert blood glucose meter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aviva Nano blood glucose meter
Study: NCT03157401

Intervention type: DRUG
Intervention: intravenous infusion group
Description: In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.

Intervention type: DRUG
Intervention: intra-articular injection group
Description: In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
Study: NCT06193291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feet heating
Description: Feet placed in hot water

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calf heating
Description: Feet to calves placed in hot water
Study: NCT03157401

Intervention type: DRUG
Intervention: control group
Description: In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Study: NCT03356223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 400mg/day with 2 doses of 200mg 12-hour apart For each 28-day cycle, a total of 56 doses of study drug will be dispensed.~Route of administration : oral~Duration of treatment until the patient experiences an unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT00476346

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium & Vitamin D
Description: Calcium 2000mg / daily Vitamin D 800IU / daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium & Vitamin D
Description: Calcium 2000mg / daily Vitamin D 800IU / daily
Study: NCT02653508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Activity
Description: During all the following meetings, before the initiation of the training sessions, 10 to 15 minutes were devoted to an interactive discussion with participants on food pyramid, food choices, food labels, food preparation and cooking, eating habits, regular meals, controlling environments that stimulate overeating. All adolescents participated in a three-day per week training programme (45 minutes per training session). Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity
Description: All adolescents participated in a three-day per week training programme (45 minutes per training session). Training was directed by a professional teacher of physical education in a public training centre. The training program was designed according to the type and intensity of exercise that school children normally perform. Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills. In order to encourage adolescents' behaviour change, they were instructed to add an extra 30-45 minutes of walking or other sport activity of their preference at least once a week and to reduce inactivity
Study: NCT02802995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP/thrombin mixture
Description: Mixture of platelet rich plasma and thrombin applied topically on the wound surface
Study: NCT03856866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine: 4mg/kg/day, divided bid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.
Study: NCT01384318

Intervention type: OTHER
Intervention: Manometer
Description: Measuring cuff pressure
Study: NCT02829697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Perineural injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Perineural injection.